Adaptive Biotechnologies Corp vs Celsius Holdings, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Celsius Holdings, Inc. trades at $28 (market cap $7.11B). The key difference: Celsius Holdings, Inc. is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Celsius Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| ADPT | CELH | |
|---|---|---|
Market Cap | $4.04B | $7.11B |
Sector | Health | Consumer Staples |
52-Week High | $25.45 | $64.86 |
52-Week Low | $12.30 | $23.77 |
Enterprise Value | $4.10B | $8.90B |
Trailing returns across standard periods
Latest headlines on both assets
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →